It's hard to think beyond targeting AR in metastatic prostate cancer when it keeps being an effective target. A new AR antagonist, SHR3680. Paper: https://t.co/2HdX2JwPHv #ASCO22 https://t.co/zEE3y0akqK
1,957 followers
9,404 followers
A phase I/II trial studying activity and safety of #SHR3680, a novel #antiandrogen, in patients with metastatic castration-resistant #prostatecancer. Read it here: https://t.co/Xz5PA2OXF6 https://t.co/69x4utSfaw
9,404 followers
NEW in BMC Medicine: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial https://t.co/Xz5PA2OXF6
906 followers
New article: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial https://t.co/H3X6aDJQTt #prostatecancer #oncology https://t.co/N6VKnmNR3y